Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Daiichi Sankyo.

Community Practice Connections™: Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan Tumor Perspective

Release Date: December 23, 2020
Expiration Date: December 23, 2021

Activity Overview

Community Practice Connections™: Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan Tumor Perspective consists of a series of short summaries of clinical data and concise video interviews with leading experts in breast, gastrointestinal, and lung cancers. The video interviews provide expert perspectives on the clinical data and address questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward a global audience of medical oncologists, pathologists, and fellows interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, pulmonologists, and other health care professionals involved in the treatment and management of patients with cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine the rationale underlying the use of antibody-drug conjugates in solid tumors
  • Apply optimized human epidermal growth factor receptor 2 (HER2) testing strategies to facilitate molecular characterization of solid tumors
  • Evaluate ongoing clinical trials and evolving data sets for novel antibody-drug conjugate targeted therapies across solid tumors
  • Integrate novel antibody-drug conjugate approaches into the care of patients with a variety of solid tumor types

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Masakazu Toi, MD, PhD
Masakazu Toi, MD, PhD
Director, Breast Cancer Unit
Kyoto University Hospital
Professor of Breast Surgery
Graduate School of Medicine
Kyoto University
Kyoto, Japan

Disclosures: Grant/Research Support: AFI Technology, Astellas Pharma, AstraZeneca, Chugai Pharmaceutical Co., Eisai, GL Sciences, Japan Breast Cancer Research Group, Kayaku Advanced Materials, Kyowa Kirin, Luxonus, Nippon, Shimadzu Corporation, Taiho Oncology, Yakult; Consultant: Athenex Oncology, Bertis, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Kyowa Kirin, Terumo Corporation; Speakers Bureau: Pfizer.

Maurice Pérol, MD
Maurice Pérol, MD
Medical Oncologist
Léon Bérard Cancer Center
Lyon, France

Disclosures: Grant/Research Support: Hoffmann-La Roche, AstraZeneca, Takeda Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical Co.; Consultant: Eli Lilly and Company, Hoffman-La Roche, AstraZeneca, Pfizer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Takeda Pharmaceutical Company, Novartis; Gritstone Oncology; Speakers’ Bureau: Eli Lilly and Company, Hoffmann-La Roche, AstraZeneca, Pfizer, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Takeda Pharmaceutical Company, Novartis, Illumina, Chugai Pharmaceutical Co.

Josep Tabernero, MD, PhD
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Vall d’Hebron University Hospital
Director, Vall d’Hebron Institute of Oncology
Vall d’Hebron Hospital
Professor of Medicine
Universitat de Vic, Universitat Central de Catalunya
Barcelona, Spain

Disclosures: Consultant: Array Biopharma, AstraZeneca, Bayer Healthcare, BeiGene, Biocartis, Boehringer Ingelheim, Chugai Pharmaceutical Co., Eli Lilly and Company, Foundation Medicine, Genentech, Genmab A/S, HalioDx SAS, Halozyme Therapeutics, Hoffmann-La Roche, Imugene, Inflection Biosciences, Ipsen Pharma, Kura Oncology, Menarini Group, Merck Serono, Merck Sharp & Dohme, Merrimack Pharmaceuticals, Merus, Molecular Partners, Novartis Pharmaceuticals, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, Roche Diagnostics, Sanofi, Seagen, Seattle Genetics, Servier Laboratories, Symphogen, Taiho Oncology, VCN Biosciences.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By